227 related articles for article (PubMed ID: 27560968)
21. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
[TBL] [Abstract][Full Text] [Related]
22. Discontinuation of tenofovir due to nephrotoxicity: insight into 12 years of clinical practice.
Matłosz B; Kowalska JD; Bąkowska E; Firląg-Burkacka E; Vassilenko A; Horban A
Przegl Epidemiol; 2019; 73(2):249-255. PubMed ID: 31385682
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
24. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients.
Tan Q; He YH; Yang TT; Yan DM; Wang Y; Zhao X; Liu HX; He SH; Zhou ZH
J Microbiol Immunol Infect; 2019 Oct; 52(5):710-719. PubMed ID: 31427111
[TBL] [Abstract][Full Text] [Related]
25. Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.
Liegeon G; Harrison L; Nechba A; Halue G; Banchongkit S; Nilmanat A; Yutthakasemsunt N; Pathipvanich P; Thongpaen S; Lertkoonalak R; Althaus T; Lallemant M; Mary JY; Jourdain G
J Infect; 2019 Nov; 79(5):454-461. PubMed ID: 31401085
[TBL] [Abstract][Full Text] [Related]
26. Association of Urinary Biomarkers of Kidney Injury with Estimated GFR Decline in HIV-Infected Individuals following Tenofovir Disoproxil Fumarate Initiation.
Ascher SB; Scherzer R; Estrella MM; Zhang WR; Muiru AN; Jotwani V; Grunfeld C; Parikh CR; Gustafson D; Young M; Sharma A; Cohen MH; Ng DK; Palella FJ; Witt MD; Ho K; Shlipak MG
Clin J Am Soc Nephrol; 2018 Sep; 13(9):1321-1329. PubMed ID: 30154221
[TBL] [Abstract][Full Text] [Related]
27. Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.
Casado JL; Del Rey JM; Bañón S; Santiuste C; Rodriguez M; Moreno A; Perez-Elías MJ; Liaño F; Moreno S
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):416-22. PubMed ID: 26962850
[TBL] [Abstract][Full Text] [Related]
28. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.
Boyd A; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Plaisier E; Lacombe K
Antivir Ther; 2017; 22(1):31-42. PubMed ID: 27553871
[TBL] [Abstract][Full Text] [Related]
29. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
[TBL] [Abstract][Full Text] [Related]
30. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
[TBL] [Abstract][Full Text] [Related]
31. Determinants and Incidence of Chronic Kidney Disease with Tenofovir- Based Antiretroviral Therapy Regimens: A Cohort Study in HIV-Infected Adults in South China.
Liu F; Wang Y; Liu H; Chen C; Miao LB; Li ZY; Wang MC; Huang JS; Bao JF
Curr HIV Res; 2022; 20(3):242-250. PubMed ID: 36111752
[TBL] [Abstract][Full Text] [Related]
32. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
[TBL] [Abstract][Full Text] [Related]
33. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
34. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
35. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
[TBL] [Abstract][Full Text] [Related]
36. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
[TBL] [Abstract][Full Text] [Related]
37. Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.
Hsu R; Brunet L; Fusco J; Beyer A; Prajapati G; Wyatt C; Wohlfeiler M; Fusco G
HIV Med; 2021 May; 22(5):325-333. PubMed ID: 33247876
[TBL] [Abstract][Full Text] [Related]
38. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Gallant JE; Moore RD
AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
[TBL] [Abstract][Full Text] [Related]
39. Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
Lapadula G; Bernasconi DP; Casari S; Maggiolo F; Cauda R; Di Pietro M; Ladisa N; Sighinolfi L; Dal Zoppo S; Sabbatini F; Soria A; Pezzoli C; Mondi A; Costarelli S; Valsecchi MG; Torti C; Gori A;
PLoS One; 2016; 11(9):e0162320. PubMed ID: 27632369
[TBL] [Abstract][Full Text] [Related]
40. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
Wever K; van Agtmael MA; Carr A
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):78-81. PubMed ID: 20173649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
